These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11372734)

  • 21. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
    Weide R; Heymanns J; Gores A; Köppler H
    Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
    McLaughlin P; Grillo-López AJ; Link BK; Levy R; Czuczman MS; Williams ME; Heyman MR; Bence-Bruckler I; White CA; Cabanillas F; Jain V; Ho AD; Lister J; Wey K; Shen D; Dallaire BK
    J Clin Oncol; 1998 Aug; 16(8):2825-33. PubMed ID: 9704735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; Bodkin DJ; White CA; Liles TM; Royston I; Varns C; Rosenberg J; Levy R
    J Clin Oncol; 1997 Oct; 15(10):3266-74. PubMed ID: 9336364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
    Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4. Antibody therapy for malignant lymphoma.
    Tobinai K
    Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M
    Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
    Alcindor T; Witzig TE
    Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
    Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
    Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.
    Drapkin R; Di Bella NJ; Faragher DC; Harden E; Matei C; Hyman W; Mirabel M; Boehm KA; Asmar L
    Clin Lymphoma; 2003 Dec; 4(3):169-75. PubMed ID: 14715099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
    Sweetenham J; Hieke K; Kerrigan M; Howard P; Smartt PF; McIntyre AM; Townshend S
    Br J Haematol; 1999 Jul; 106(1):47-54. PubMed ID: 10444162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.
    van der Kolk LE; Grillo-López AJ; Baars JW; van Oers MH
    Leukemia; 2003 Aug; 17(8):1658-64. PubMed ID: 12886256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
    Hess G; Flohr T; Kolbe K; Bonn S; Schuler M; Derigs HG; Huber C
    Ann Hematol; 2006 Nov; 85(11):769-79. PubMed ID: 16896912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
    Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
    Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
    Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
    J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.
    Tobinai K; Igarashi T; Itoh K; Kobayashi Y; Taniwaki M; Ogura M; Kinoshita T; Hotta T; Aikawa K; Tsushita K; Hiraoka A; Matsuno Y; Nakamura S; Mori S; Ohashi Y;
    Ann Oncol; 2004 May; 15(5):821-30. PubMed ID: 15111353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
    Davis TA; White CA; Grillo-López AJ; Velásquez WS; Link B; Maloney DG; Dillman RO; Williams ME; Mohrbacher A; Weaver R; Dowden S; Levy R
    J Clin Oncol; 1999 Jun; 17(6):1851-7. PubMed ID: 10561225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
    Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
    Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.